September 25, 2017 2:14 PM ET


Company Overview of Agios Pharmaceuticals, Inc.

Key Executives for Agios Pharmaceuticals, Inc.

NameBoard RelationshipsTitleAge
David P. Schenkein M.D.52 RelationshipsCEO, President & Director60
Lewis Clayton Cantley Ph.D.86 RelationshipsCo-Founder, Director & Member of Scientific Advisory Board68
Tak Wah Mak Ph.D., D.Sc., FRSC155 RelationshipsCo-Founder & Member of Scientific Advisory Board71
Shin-San Su Ph.D.17 RelationshipsCo-Founder & Member of Scientific Advisory Board61
Craig B. Thompson M.D.134 RelationshipsCo-Founder & Chairman of Scientific Advisory Board64
View More Key Executives

Agios Pharmaceuticals, Inc. Board Members*

NameBoard RelationshipsPrimary CompanyAge
John M. Maraganore M.D., Ph.D. 157 RelationshipsAlnylam Pharmaceuticals, Inc.54
David P. Schenkein M.D. 52 RelationshipsAgios Pharmaceuticals, Inc.60
Lewis Clayton Cantley Ph.D. 86 RelationshipsAgios Pharmaceuticals, Inc.68
Tak Wah Mak Ph.D., D.Sc., FRSC 155 RelationshipsAgios Pharmaceuticals, Inc.71
Craig B. Thompson M.D. 134 RelationshipsAgios Pharmaceuticals, Inc.64
View All Board Members

Agios Pharmaceuticals, Inc. Executive Committees*

Committee NameChairpersonBoard RelationshipsMembers
Audit Committee M.B.A.Paul J. Clancy23 Relationships3 Executives
Compensation Committee Kaye I. Foster-Cheek52 Relationships2 Executives
Nominating Committee Kaye I. Foster-Cheek52 Relationships3 Executives
Corporate Governance Committee Kaye I. Foster-Cheek52 Relationships3 Executives
Advisory Board M.D.Craig B. Thompson134 Relationships11 Executives
View Committee Details
*Data is at least as current as the most recent Definitive Proxy.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup


  Industry Range
Not meaningful
Total Short Term Compensation$30.8M
Not meaningful
Total Value of Options$568.0K
Compensation as of Fiscal Year 2016
Agios Pharmaceuticals, Inc. CEO Compensation
Industry Average


Verseon Corporation Announces Resignation of Alastair Cade as Class II Non-Executive Director
September 25, 2017 6:00 AM ET
Kannalife Sciences, Inc. Announces Nick Lowery as New Spokesperson
September 23, 2017 1:50 AM ET
Eleven Biotherapeutics, Inc. Announces Resignation of Arthur Decillis as Chief Medical Officer, Effective as of October 3, 2017
September 22, 2017 8:55 PM ET
Neuralstem, Inc. Announces Board Appointments
September 22, 2017 8:30 PM ET
NantKwest, Inc. Announces Directorate Changes
September 22, 2017 8:06 PM ET

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Agios Pharmaceuticals, Inc., please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at